Evidence map›Paper›PMID 39602499›Full record

ArticleAngewandte Chemie (International ed. in English)2025

A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development.

Angela T Fan, Gillian E Gadbois, Hai-Tsang Huang, Charu Chaudhry, Jiewei Jiang, Logan H Sigua, Emily R Smith, Sitong Wu, Grace J Poirier, Kara Dunne-Dombrink and 6 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Proteomics-Driven Strategies for Proximity-Inducing Drug Discovery.Angewandte Chemie (International ed. in English) · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Direct-to-Biology Enabled Molecular Glue Discovery.Journal of the American Chemical Society · 2026
    Article
  6. PROTACs in cancer immunotherapy: a minireview.Biochemical Society transactions · 2025
    Review
  7. Methods to accelerate PROTAC drug discovery.The Biochemical journal · 2025
    Review
  8. Computational Design of Lysine Targeting Covalent Binders Using Rosetta.Journal of chemical information and modeling · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Angela T FanDepartment of Chemistry and Biochemistry, University of California, San Diego.
Gillian E GadboisDepartment of Chemistry and Biochemistry, University of California, San Diego.
Hai-Tsang HuangThe Broad Institute of Harvard and MIT.
Charu ChaudhryDiscovery Technologies Molecular Pharmacology, J&J Innovative Medicine, Spring House, Pennsylvania, 19477, United States.
Jiewei JiangDepartment of Chemistry and Biochemistry, University of California, San Diego.
Logan H SiguaMedical Scientist Training Program, University of California, San Diego.
Emily R SmithDepartment of Chemistry and Biochemistry, University of California, San Diego.
Sitong WuDepartment of Chemistry and Biochemistry, University of California, San Diego.
Grace J PoirierDepartment of Chemistry and Biochemistry, University of California, San Diego.
Kara Dunne-DombrinkDepartment of Chemistry and Biochemistry, University of California, San Diego.
Pavitra GoyalDepartment of Chemistry and Biochemistry, University of California, San Diego.
Andrew J TaoDepartment of Chemistry and Biochemistry, University of California, San Diego.
William R SellersThe Broad Institute of Harvard and MIT.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston.
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston.
Fleur M FergusonDepartment of Chemistry and Biochemistry, University of California, San Diego.ORCID https://orcid.org/0000-0003-4091-7617

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007198 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHI, NEIL C, INSEL, PAUL A · 1985 to 2024
$29.3M
Contemporary Approaches to Cancer Cell Signaling and CommunicationT32CA009523 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DONOGHUE, DANIEL J, YANG, JING · 1985 to 2025
$12.1M
Molecular Biophysics Training Grant at UC San DiegoT32GM139795 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Galia Debelouchina, ELIZABETH A. KOMIVES · 2021 to 2026
$3.0M
Chemical Control of Misfolded Protein FateDP2NS132610 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FERGUSON, FLEUR MARCIA · 2022 to 2025
$2.4M
Chemistry-Biology Interfaces at UCSDT32GM146648 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael D. Burkart, Alexis C. Komor · 2022 to 2026
$876k
NCI NIH HHS T32 CA009523NIGMS NIH HHS T32 GM007198NIGMS NIH HHS T32 GM139795NIGMS NIH HHS T32 GM146648NINDS NIH HHS DP2 NS132610
6 · The paper itself

Abstract

Bifunctional molecules such as targeted protein degraders induce proximity to promote gain-of-function pharmacology. These powerful approaches have gained broad traction across academia and the pharmaceutical industry, leading to an intensive focus on strategies that can accelerate their identification and optimization. We and others have previously used chemical proteomics to map degradable target space, and these datasets have been used to develop and train multiparameter models to extend degradability predictions across the proteome. In this study, we now turn our attention to develop generalizable chemistry strategies to accelerate the development of new bifunctional degraders. We implement lysine-targeted reversible-covalent chemistry to rationally tune the binding kinetics at the protein-of-interest across a set of 25 targets. We define an unbiased workflow consisting of global proteomics analysis, IP/MS of ternary complexes and the E-STUB assay, to mechanistically characterize the effects of ligand residence time on targeted protein degradation and formulate hypotheses about the rate-limiting step of degradation for each target. Our key finding is that target residence time is a major determinant of degrader activity, and this can be rapidly and rationally tuned through the synthesis of a minimal number of analogues to accelerate early degrader discovery and optimization.

Indexed as

ProteinsHumansKineticsLigandsProteolysisProteomicsLigandsProteinscompound residence timePROTACsproteasomal degradationproteomicsTargeted protein degradation

Identifiers

PMID39602499
PMCPMC11890178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.